An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).
Lu S, Cheng Y, Zhou J, Wang M, Zhao J, Wang B, Chen G, Feng J, Ma Z, Wu L, Wang C, Ma K, Zhang S, Liang J, Song Y, Wang J, Wu YL, Li A, Huang Y, Chang J.
Lu S, et al. Among authors: huang y.
Ther Adv Med Oncol. 2022 Nov 19;14:17588359221138380. doi: 10.1177/17588359221138380. eCollection 2022.
Ther Adv Med Oncol. 2022.
PMID: 36425873
Free PMC article.